(NASDAQ: JANX) Janux Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.03%.
Janux Therapeutics's earnings in 2026 is -$113,625,000.On average, 20 Wall Street analysts forecast JANX's earnings for 2026 to be -$167,250,555, with the lowest JANX earnings forecast at -$217,594,834, and the highest JANX earnings forecast at -$116,249,295. On average, 17 Wall Street analysts forecast JANX's earnings for 2027 to be -$202,618,080, with the lowest JANX earnings forecast at -$355,305,536, and the highest JANX earnings forecast at -$104,946,773.
In 2028, JANX is forecast to generate -$243,229,293 in earnings, with the lowest earnings forecast at -$362,459,339 and the highest earnings forecast at -$171,819,012.